Price on Abbott Laboratories (ABT) has officially completed its active bullish sequence, with the expansion leg reaching the defined Point C target zone ($115.00 – $120.00). This culmination occurred directly within the higher-timeframe BC correction zone, creating an ideal confluence for structural exhaustion after a sustained multi-month rally off the May lows.
Following the sequence fulfillment, price aggressively engineered a run above the prior March highs to sweep resting External Liquidity. The subsequent reaction yielded sharp downside displacement and printed a clean Market Structure Shift (MSS) on the 4-Hour timeframe, signaling that institutional participants are actively distributing and that local momentum has shifted decisively in favor of sellers.
With the bullish sequence terminated and structural confirmation in place, the path is now open for a corrective rotation toward the Whole Correction Level (WCL) spanning $93.50 – $100.00. This downside objective coincides directly with resting Internal Liquidity around the psychological $100.00 handle and the original sequence breakout base, presenting a high-probability target zone for the ongoing cycle.
Following the sequence fulfillment, price aggressively engineered a run above the prior March highs to sweep resting External Liquidity. The subsequent reaction yielded sharp downside displacement and printed a clean Market Structure Shift (MSS) on the 4-Hour timeframe, signaling that institutional participants are actively distributing and that local momentum has shifted decisively in favor of sellers.
With the bullish sequence terminated and structural confirmation in place, the path is now open for a corrective rotation toward the Whole Correction Level (WCL) spanning $93.50 – $100.00. This downside objective coincides directly with resting Internal Liquidity around the psychological $100.00 handle and the original sequence breakout base, presenting a high-probability target zone for the ongoing cycle.
Dagangan ditutup: sasaran tercapai
Penafian
Maklumat dan penerbitan adalah tidak bertujuan, dan tidak membentuk, nasihat atau cadangan kewangan, pelaburan, dagangan atau jenis lain yang diberikan atau disahkan oleh TradingView. Baca lebih dalam Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak bertujuan, dan tidak membentuk, nasihat atau cadangan kewangan, pelaburan, dagangan atau jenis lain yang diberikan atau disahkan oleh TradingView. Baca lebih dalam Terma Penggunaan.